---
title: Genotype, Oxidase Status, and Preceding Infection or Autoinflammation Do Not
  Affect Allogeneic HCT Outcomes for CGD
date: '2023-08-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37562003/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230811181201&v=2.17.9.post6+86293ac
source: Blood
description: Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized
  by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation
  (HCT) is the definitive treatment for CGD, but questions remain regarding patient
  selection and impact of active disease on transplant outcomes. We performed a multi-institutional
  retrospective and prospective study of 391 patients with CGD treated either conventionally
  (non-HCT;n=151) enrolled from 2004-2018 or ...
disable_comments: true
---
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT;n=151) enrolled from 2004-2018 or ...